SG Americas Securities LLC Raises Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

SG Americas Securities LLC grew its holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 23.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 42,521 shares of the company’s stock after buying an additional 8,024 shares during the period. SG Americas Securities LLC owned approximately 0.05% of Atea Pharmaceuticals worth $130,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Gladius Capital Management LP boosted its stake in shares of Atea Pharmaceuticals by 98.2% during the 3rd quarter. Gladius Capital Management LP now owns 8,581 shares of the company’s stock worth $26,000 after purchasing an additional 4,251 shares during the period. Vanguard Group Inc. boosted its stake in shares of Atea Pharmaceuticals by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 4,573,440 shares of the company’s stock worth $13,720,000 after purchasing an additional 55,841 shares during the period. American Century Companies Inc. boosted its stake in shares of Atea Pharmaceuticals by 62.5% during the 3rd quarter. American Century Companies Inc. now owns 55,893 shares of the company’s stock worth $168,000 after purchasing an additional 21,503 shares during the period. GSA Capital Partners LLP boosted its stake in shares of Atea Pharmaceuticals by 41.9% during the 3rd quarter. GSA Capital Partners LLP now owns 278,286 shares of the company’s stock worth $835,000 after purchasing an additional 82,208 shares during the period. Finally, Sectoral Asset Management Inc. boosted its stake in shares of Atea Pharmaceuticals by 19.7% during the 3rd quarter. Sectoral Asset Management Inc. now owns 600,461 shares of the company’s stock worth $1,801,000 after purchasing an additional 98,924 shares during the period. 86.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Atea Pharmaceuticals

In other Atea Pharmaceuticals news, CEO Jean-Pierre Sommadossi sold 56,910 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $3.85, for a total value of $219,103.50. Following the completion of the sale, the chief executive officer now directly owns 116,557 shares of the company’s stock, valued at approximately $448,744.45. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Atea Pharmaceuticals news, CEO Jean-Pierre Sommadossi sold 56,910 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $3.85, for a total value of $219,103.50. Following the completion of the sale, the chief executive officer now directly owns 116,557 shares of the company’s stock, valued at approximately $448,744.45. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Wayne Foster sold 12,477 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $3.84, for a total transaction of $47,911.68. Following the completion of the sale, the chief accounting officer now directly owns 20,857 shares of the company’s stock, valued at $80,090.88. The disclosure for this sale can be found here. Insiders sold a total of 85,230 shares of company stock valued at $327,852 in the last three months. Company insiders own 14.50% of the company’s stock.

Atea Pharmaceuticals Trading Down 0.8 %

AVIR stock opened at $3.71 on Thursday. Atea Pharmaceuticals, Inc. has a 12 month low of $2.77 and a 12 month high of $5.19. The company has a 50-day moving average price of $4.02 and a 200 day moving average price of $3.50. The stock has a market cap of $312.25 million, a PE ratio of -2.26 and a beta of 0.16.

Atea Pharmaceuticals (NASDAQ:AVIR) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). Sell-side analysts forecast that Atea Pharmaceuticals, Inc. will post -2.76 EPS for the current year.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.